AAIC 2025 Abstract
GABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participants
Trial in peoplePopulations
Abstract
Background: RG6289 is a novel, potent and selective oral γ‐secretase modulator (GSM) in development for Alzheimer’s disease (AD).
